中文
English
한국어
日本語
Español
Français
Русский
| カタログ番号 | CY257020 |
|---|---|
| 説明 |
InVivoMAb Anti-Dog CD20/MS4A1 Antibody (Iv0177) [Iv0177] (CY257020) is a dog monoclonal antibody detecting B-lymphocyte surface antigen B1 in ELISA, Neutralization. Suitable for Dog.
|
| 種反応性 | Canine |
| アプリケーション | ELISA, Neutralization |
| 宿主種 | Canine |
| クローン性 | Monoclonal |
| アイソタイプ | IgG2, kappa |
| クローンID | Iv0177 |
| ターゲット | B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, CD20, Leukocyte surface antigen Leu-16, MS4A1, Membrane-spanning 4-domains subfamily A member 1 |
| エンドトキシンレベル | < 1 EU/mg |
| 純度 | >95% as determined by SDS-PAGE. |
| 関連製品 | pH 7.4 Dilution Buffer |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | Q3C2E2 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 背景 | B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva). |
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for InVivoMAb Anti-Canine CD20 Antibody (Iv0177)
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
